

Japan's Shionogi continues rare disease expansion with acquisition of IntraBio for \$2 B

October 8, 2026 | News

Transaction will add AQNEURSA® (levacetyleucine) to Shionogi's expanding rare disease portfolio



Japan-based Shionogi & Co. is entering into an agreement to acquire IntraBio Inc, a biopharmaceutical company developing and commercialising therapies for neurodegenerative diseases.

Pursuant to the agreement, which was signed by the parties, IntraBio would become a wholly owned subsidiary of Shionogi Inc., a New Jersey-based subsidiary of Shionogi.

The proposed transaction, which is subject to customary closing conditions, would add AQNEURSA® (levacetyleucine) and IntraBio's capabilities in the rare disease area to Shionogi's growing portfolio.

AQNEURSA was approved by the FDA in September 2024 for neurological manifestations of Niemann-Pick disease Type C (NPC) in adults and pediatric patients and by the European Medicines Agency (EMA) in January 2026.

It was approved by the FDA for the treatment of Ataxia in adults and pediatric patients diagnosed with Ataxia-Telangiectasia (A-T) on September 18, 2026. AQNEURSA is currently under review by the EMA for adult and pediatric patients diagnosed with A-T.

Since acquiring the global rights to edaravone, a treatment for amyotrophic lateral sclerosis (ALS), known as RADICAVA® in the US and RADICUT® in Japan, in April 2026, Shionogi has established a strong commercial foundation in rare disease, including expertise in serving patients with serious neurological diseases.

Under the terms of the agreement, Shionogi Inc. will acquire all outstanding shares of IntraBio for an upfront consideration of \$2 billion payable to IntraBio shareholders.